Explore the NIHProtocol Details
Diagnosis and Treatment of Leishmanial Infections
This study is currently recruiting participants.
Summary | Eligibility | Citations | Contacts
Summary
Number |
01-I-0238 |
Sponsoring Institute |
National Institute of Allergy and Infectious Diseases (NIAID) |
Recruitment Detail |
Type: Participants currently recruited/enrolled |
Referral Letter Required |
Yes |
Population Exclusion(s) |
None |
Special Instructions |
Currently Not Provided |
Keywords |
Cutaneous; |
Recruitment Keyword(s) |
Leishmanial Infection; |
Condition(s) |
Leishmaniasis |
Investigational Drug(s) |
Pentostam |
Investigational Device(s) |
None |
Intervention(s) |
None |
Supporting Site |
|
Participants will have routine blood tests and a biopsy to confirm leishmanial infection. The biopsy procedure will be determined by the type of infection-local cutaneous leishmaniasis (LCL), mucocutaneous leishmaniasis (MCL) or visceral leishmaniasis (VL). CL will be confirmed with a punch biopsy, in which a cookie-cutter type razor is used to remove a small circular piece of skin tissue. MCL will be confirmed using a thin flexible tube inserted into the nose. This tube is used to examine the nose and upper airway and to remove a tissue sample, if an affected area is seen. VL will be confirmed with either a bone marrow or liver biopsy or a splenic aspirate. For these procedures, a small tissue sample is withdrawn through a needle placed in the hipbone, liver or spleen, respectively. Some patients may also have a skin test for leishmaniasis similar to tuberculin skin testing.
Treatment and length of hospital stay are determined by the type of infection. CL may be treated with Pentostam, amphotericin, amphotericin B, itraconazole or ketoconazole; ML with amphotericin B, or encapsulated amphotericin; and VL with Pentostam or encapsulated amphotericin. Pentostam is infused daily for 18 to 28 doses, most as an outpatient. Blood is drawn 3 times a week for safety tests and an electrocardiogram is done 2 to 3 times a week to monitor heart rhythm. Amphotericin B is infused every day or every other day for about 30 doses, all on an inpatient basis. Patients undergo hydration (infusion of a large amount of fluid) just before and immediately after each infusion to protect the kidneys. Blood is drawn every other day and urine samples are collected occasionally for routine urinalysis. Encapsulated amphotericin is infused every other day, on an outpatient basis. Blood is generally drawn every other day to every 2 days and urinalyses are done periodically. Itraconazole and ketoconazole are taken orally for at least 1 to 3 months, with blood drawn every 2 to 3 weeks.
Patients may be asked to have photographs taken before, during and after treatment to document progress. They may also be asked to provide extra blood samples for research purposes, either through a vein in the arm or through apheresis, a method for collecting large numbers of cells. For apheresis, whole blood is collected through a needle in an arm vein and circulated through a machine that separates it into its components. The desired cells are then removed, and the rest of the blood is returned to the body, either through the same needle used to draw the blood or through a second needle in the other arm.
Patients with cutaneous leishmaniasis will have a follow-up clinic visit 2 weeks to 3 months after treatment is completed. If there are no complications, their participation will end at that time. Patients with mucocutaneous leishmaniasis and visceral leishmaniasis will be followed every 3 to 6 months indefinitely for routine evaluations and re-treatment if the infection recurs.
Eligibility
INCLUSION CRITERIA:
Individuals of either sex must be between the ages of 2 and 80 years.
Individuals must have a parasitologic diagnosis confirmed by culture or PCR at the NIH. In some instances, a diagnosis established at some other facility, or based upon clinical and convincing histopathological evidence may allow inclusion.
EXCLUSION CRITERIA:
Individuals who are pregnant or breast feeding, who do not have a life-threatening form of this disease, will be excluded from this protocol until termination of pregnancy (birth or otherwise). Those with life-threatening leishmaniasis will be offered treatment.
Those who refuse recommended treatments, evaluations, or follow up
Presence of other life threatening illness and non serious leishmaniasis
When treatment is not in the best interest of the patient's well being
Citations:
Not ProvidedContacts:
Principal Investigator |
Referral Contact |
For more information http://clinicalstudies.info.nih.gov. |
| Theodore E. Nash, M.D. National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Building 10 CRC Room 12C103 10 Center Drive Bethesda, Maryland 20892-1684 (301) 451-9035 guzel@mail.nih.gov |
Theodore E. Nash, M.D. National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Building 10 CRC Room 12C103 10 Center Drive Bethesda, Maryland 20892-1684 (301) 451-9035 guzel@mail.nih.gov |
Patient Recruitment and Public Liaison Office Building 61 10 Cloister Court Bethesda, Maryland 20892-4754 Toll Free: 1-800-411-1222 TTY: 301-594-9774 (local),1-866-411-1010 (toll free) Fax: 301-480-9793 prpl@mail.cc.nih.gov |
Clinical Trials Number:
NCT00344188
QUESTIONS?
Contact the Patient Recruitment and Public Liaison Office for:
- Details on how to participate in a study
- Details on how to refer a patient to a study
NIH Clinical Studies Information Request
Contact the Office of Communications for:
- General information about the NIH Clinical Center
Contact the Department Clinical Research Informatics, (DCRI) for:
- Technical questions about Adobe Acrobat and the PDF format
- Technical questions about this web server
